ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts
BioCentury’s analysis of ASCO 2019 abstracts shows bispecifics outpacing CAR Ts in solid tumors
While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via new strategies.
BioCentury’s fourth annual survey of abstracts at the American Society of Clinical Oncology (ASCO) meeting presents a snapshot of clinical research in cancer, according to a machine learning-based analysis of 4,627 abstracts for mentions of products, indications, targets, modalities or other hot topic terms.
The 2019 analysis documents 31 novel targets and 22 products in first-in-human trials presented at the meeting, as well as trends in two technologies to improve clinical trials and regulatory decisions (see Table: “ASCO 2019 New Targets” and “Clinical Trial and Regulatory Efficiency Get Help from ctDNA, RWE at ASCO19”).
The 2019 analysis documents 31 novel targets and 22 products in first-in-human trials presented at the meeting.
New modalities continue to advance, with nine of the first-in-human products outside of traditional small molecule and antibody modalities (see Table: “ASCO 2019 First-in-Human Abstracts”).
Bispecific antibodies threaten to steal the show. Though the total number of abstracts mentioning bispecifics -- including one tetraspecific compound -- is still less than some other new modalities, the class showed a substantial surge in activity this year over last (see Figure: “ASCO 2019 Modalities”).
Figure: ASCO 2019 modalities
New modalities continue to be well represented at this year’s American Society of Clinical Oncology (ASCO) meeting. Though bispecific antibodies rank sixth for the number of mentions in abstracts, the class saw the biggest rise over 2018 among the new modalities, followed by CAR T cell therapies. Top graph shows the number of abstracts in 2019; bottom graph shows percent change from 2018. While the number of ADC abstracts fell this year, four products will have first-in-human data presented.
Modalities were identified using a machine learning-based text search of abstracts assigned to any of ASCO’s presentation tracks related to clinical, preclinical or basic research. Exosomes and liposomes were categorized as nanoparticles, and include liposomal chemotherapy formulations. The vaccine category includes DNA, neoantigen, peptide and RNA vaccines. The nucleic acid category includes antisense oligonucleotides, siRNA, shRNA, microRNA (miRNA), long noncoding RNA (lncRNA) and small activating RNA (saRNA). The bispecific category contains one abstract describing tetraspecific antibodies. The other cell therapy category includes all cell therapies minus CAR T cells. mAbs and small molecules were excluded from this analysis. The analysis also excluded abstracts assigned to tracks